In what can be described as one of the most strategic joint ventures to happen in the international pharmaceutical landscape, Sygen Pharmaceuticals Limited Lagos, Nigeria and ORx Pharmaceuticals Corporation, Ontario Canada, have come together in a synergistic partnership known as Sygen-ORx Biosciences with the aim of revolutionising healthcare and addressing pharmaceutical drug security challenges through collaborative innovation.
Speaking at the official unveiling of the joint venture on Friday, 16 August,2024, CEO of ORx Pharmaceuticals Corporation, Dr Alexander MacGregor, said Sygen-ORx Biosciences would leverage the pedigree of excellence already built by Sygen and ORx in a new era of healthcare innovation.
“With a shared commitment to scientific excellence and integrity, Sygen-ORx Biosciences is positioned to make a significant impact in the healthcare landscape, shaping the future of medicine for generations to come,” he said.
On his part, the CEO of Sygen Pharmaceuticals Limited, Mr Charles Ogunwuyi reiterated the commitment of Sygen Pharmaceutical Limited towards sustaining the culture of strategic collaborations in its mission to engender innovative outcomes in the healthcare space.
“Collaboration is at the heart of our mission at Sygen Pharmaceuticals and we are excited to embark on this transformative journey with ORx Pharmaceuticals. Together as Sygen-ORx, we have the opportunity to amplify our impact and drive innovation in healthcare, ultimately improving the lives of patients in Africa and beyond.
“Through our partnership with ORx Pharmaceuticals, we can leverage our collective strengths to deliver meaningful solutions that address critical medical challenges and advance patient care,” he said.
During her keynote address, Director-General of the National Agency for Food and Drug Administration and Control (NAFDAC), Professor Mojisola Adeyeye, extolled the partnership between Sygen Pharmaceuticals and ORx Pharmaceuticals.
She added that NAFDAC had always worked towards creating the enabling environment for synergies that would enhance the healthcare space in Nigeria, especially by ensuring that Nigeria depends less on foreign sources for its medicines.
She also pointed out that what is happening between Sygen and ORx is one of the manifestations of some of the steps that had been taken by the apex food and drug regulator.
“The impact of what is happening today will be hugely felt in about 4 to 5 years from now. NAFDAC started an inward-looking journey 6 years ago. We wanted to become less addictive to foreign drugs and so we started different regulatory directives to encourage local manufacturing.
“Changes being witnessed in the industry today are manifestations of changes that took place in NAFDAC,” she added.
The joint venture between Sygen and ORx represents a powerful unio of vision, expertise and commitment to improving patient outcomes and tackling pharmaceutical drug security challenges.
By combining resources, knowledge and capabilities, Sygen-ORx aims to accelerate the development and commercialisation of cutting-edge therapies, addressing unmet medical needs and improving healthcare access for patients worldwide.
The joint venture company will focus on the development of improved formulations of generic pharmaceuticals, focusing on products with established clinical efficacy, which have already received regulatory approval and achieved substantial commercial success.
It will also advance innovative drug discovery programmes into regional and global pharmaceutical market place and reduce cost and increase access to high quality branded generic medicines in Africa.
